Welcome to SweCROPT
About SweCROPT
SweCROPT’s aims and structure
The Swedish Consortium for Research on Organised Prostate Cancer Testing (SweCROPT) was formed in 2022 to co-ordinariate Swedish OPT related research. Its aims are:
- To be a forum for scientific ideas and experiences related to OPT research
- To facilitate national studies with better statistical power than regional studies
- To facilitate studies comparing diagnostic outcomes of regional OPT variants
- To prevent parallel studies of similar research questions by different research groups
SweCROPT is open to all researchers and doctoral students who are engaged in research directly related to the Swedish regional OPT projects. The SweCROPT network has six working groups (WGs) representing different areas of OPT research. Each WG is led by a co-ordinator. They arrange WG-specific meetings for planning and executing research. SweCROPT also arranges national meetings to discuss recent research results and to facilitate creative interaction between researchers from different research disciplines and environments.
Chairman: Ola Bratt, Professor of Clinical Cancer Epidemiology, University of Gothenburg.
SweCROPT’s Working Groups
Working Group 1: Register-based research: Diagnostic outcomes and socioeconomic equity
Co-ordinator: Professor Ola Bratt, University of Gothenburg
Working Group 2: Improving diagnostic imaging
Co-ordinator: Professor Sophia Zackrisson, Lund University
Working Group 3: Biobanking
Co-ordinator: Associate Professor Andreas Josefsson, Umeå University
Workning Group 4: Psychosocial consequences and informatics
Co-ordinator: Associate Professor Anetta Bolejko, Lund University
Working Group 5: Health economy
Co-ordinator: Shuang Hao, Ph.D., Karolinska Institute, Stockholm
Publications
WG 1
Bratt O, Andersson-Säll T, Arnsrud Godtman R, Bjartell A, Gunnarsson O, Lantz A, Styrke J. Movember moustache campaign and participation in Swedish organised prostate cancer testing. Scand J Urol. 2025 Dec 10;60:226-228. doi: 10.2340/sju.v60.45025.
Arvendell M, Abbadi A, Phillips L, Crippa A, Nordström T, Lantz A. Socioeconomic Status and Prostate-specific Antigen Testing: A Population-based Cohort Study Comparing Organised and Opportunistic Prostate Cancer Testing. Eur Urol Focus. 2025 Dec. PMID: 41455654
Bratt, O., Butt, S. T., Carlsson, C., Jelf-Eneqvist, L., Gunnarsson, O., Ihre, A., … Arnsrud Godtman, R. (2025). Swedish regional population-based organised prostate cancer testing: why, what and how?. Scandinavian Journal of Urology, 60, 97–104. PMID: 40458846
Järbur E, Godtman RA, Bonander C, Strömberg U, Bratt O (2025) Associations between neighbourhood characteristics and participation in a population-based organised prostate cancer testing (OPT) programme: A register-based study of 50-year-old men. PLoS One 20(4): e0322643. PMID: 40300134
Järbur E, Holmberg E, Björk-Eriksson T, Bratt O, Arnsrud Godtman R. Associations between socioeconomic factors and PSA testing in a population-based organised testing programme and routine healthcare: a register-based study of 50-year-old men. BMJ Oncol. 2024 Sep 18;3(1):e000400. PMID: 39886157.
Bratt O, Godtman RA, Jiborn T, Wallström J, Akre O, Carlsson S, Nordström T, Thimansson E, Alterbeck M, Zackrisson S, Hugosson J, Bjartell A, Lantz A. Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men. Eur Urol. 2024 Mar;85(3):207-214. Epub 2023 Dec 1. PMID: 38042646.
WG 2
Huang, V., Dang, H., Thimansson, E. et al. Incidental findings on prostate MRI in a population-based screening setting. Insights Imaging 16, 261 (2025). PMID: 41284149
Wallström J, Alterbeck M, Godtman RA, Bratt O, Jiborn T, Thimansson E. A Comparison of Magnetic Resonance Imaging Assessment and Biopsy Outcomes with and Without Central Review in Two Swedish Regional Organized Prostate Cancer Testing Programs. Eur Urol Open Sci. 2025 Jun 5;77:32-38. PMID: 40528941
Thimansson E, Zackrisson S, Jäderling F, Alterbeck M, Jiborn T, Bjartell A, Wallström J. A pilot study of AI-assisted reading of prostate MRI in Organized Prostate Cancer Testing. Acta Oncol. 2024 Oct 29;63:816-821. PMID: 39473176
WG 3
WG 4
Arvendell M, Abbadi A, Phillips L, Crippa A, Nordström T, Lantz A. Socioeconomic Status and Prostate-specific Antigen Testing: A Population-based Cohort Study Comparing Organised and Opportunistic Prostate Cancer Testing. Eur Urol Focus. 2025 Dec 26:S2405-4569(25)00263-9. PMID: 41455654 Epub ahead of print.
Olsson K, Delilovic S, Enelius MB, Hägglund A, Lantz A, Richter A. Men’s experiences of the Swedish Organised Prostate Cancer Testing programme: a qualitative study. BJU Int. 2025 Aug;136(2):254-260. Epub 2025 Apr 6. PMID: 40189214.
Svensson L, Bratt O, Hugosson J, Stinesen K. Prostate Cancer Screening Decisions: Which Aspects Do Men Value Most? An Interview Study With Men Invited to a Population-Based Program. Am J Mens Health. 2025 May-Jun;19(3):15579883251344563. Epub 2025 Jun 23. PMID: 40548674.
Arvendell M, Phillips L, Delilovic S, Enelius MB, Olsson K, Bolejko A, Akre O, Carlsson S, Richter A, Lantz A. Men’s Attitudes Towards Participation in Organised Prostate Cancer Testing: An Abductive Thematic Analysis. Eur Urol Open Sci. 2024 Dec 27;71:156-164. PMID: 39834916.
Svensson L, Stinesen Bratt K, Jiborn T, Börjedahl AC, Bratt O. Men’s Perception of Being Invited for Prostate Cancer Testing and the Information About Its Pros and Cons-A Survey from Two Population-based Testing Programmes. Eur Urol Open Sci. 2023 May 2;52:66-71. PMID: 37284038.
WG 5
Skalt D, Chen T, Abbadi A, Lantz A, Discacciati A, Eklund M, Clements M, Nordström T, Hao S. Prostate Cancer Testing Between Screening Rounds: Evidence from the STHLM3-MRI Trial. Eur Urol Oncol. 2025 Aug;8(4):1070-1077. PMID: 40544091. Epub 2025 Jun 20.
Contact
Working Group 1
Professor Ola Bratt, University of Gothenburg.
ola.bratt@vgregion.se
Working Group 2
Professor Sophia Zackrisson, Lund University
sophia.zackrisson@med.lu.se
Working Group 3
Associate Professor Andreas Josefsson, Umeå University
Workning Group 4
Associate Professor Anetta Bolejko, Lund University
anetta.bolejko@med.lu.se
Working Group 5
Shuang Hao, Ph.D., Karolinska Institute, Stockholm
shuang.hao@ki.se